On LinkedIn19 Feb 2026 07:25
Immunotherapies bring the promise of a cancer -free future – and we’re excited to share our perspectives with the community in a Lumanity event next week.
Scancell CEO Phil L'Huillier will take part in a webinar with other leading biotech/healthcare executives Lisa Butterfield, Michael Kalos, plus Mai-Britt Zocca, Alan Rigby and Marina Udier Blagovic on “Have Cancer Vaccines Come of Age (or Do They Remain the Unruly Adolescent)?”
The panel will discuss how learnings from past cancer vaccine efforts and an increased understanding of tumor-immune system interactions, further enabled by checkpoints inhibitors, have resulted in important innovations in the targets, immunisation platforms and clinical trial designs.
Phil will give insights from his and our experience, including from the recent positive Phase 2 data from the SCOPE trial of our lead ImmunoBody® iSCIB1+ in combination with checkpoint inhibitors in advanced melanoma - and perspectives ahead to the registrational Phase 3 trial expected to start this year.
The event takes place on Tuesday, February 24 at https://lnkd.in/exEnfE-U
#Biotech #Cancer #Immunotuerapies #Webinar #CEOInsights #Oncology #ImmunoBody #Vaccines